<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03993613</url>
  </required_header>
  <id_info>
    <org_study_id>MD2014.01</org_study_id>
    <nct_id>NCT03993613</nct_id>
  </id_info>
  <brief_title>Apotransferrin in Patients With β-thalassemia</brief_title>
  <official_title>Efficacy and Safety of Human Apotransferrin in Patients With β-thalassemia Intermedia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanquin Plasma Products BV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanquin Plasma Products BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to study the effect of apotransferrin administration in patients
      suffering from β-thalassemia intermedia in order to restore the erythropoiesis as reflected
      by enhanced haemoglobin levels or reduced transfusion dependency.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erythropoiesis</measure>
    <time_frame>17 weeks</time_frame>
    <description>Change of haemoglobin level and/or or change of number of RBC units transfused/week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum iron</measure>
    <time_frame>17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in change plasma levels of advanced glycation end products</measure>
    <time_frame>17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in spleen size</measure>
    <time_frame>at baseline and at 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in reticulocyte count</measure>
    <time_frame>17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in erythropoietin levels</measure>
    <time_frame>17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>predose and postdose 5 minutes, 2 hours and 1, 4, 7, 14 days</time_frame>
    <description>Ctrough calculated from serum transferrin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin</measure>
    <time_frame>predose and postdose 5 minutes, 2 hours and 1, 4, 7, 14 days</time_frame>
    <description>Cmin calculated from serum transferrin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>predose and postdose 5 minutes, 2 hours and 1, 4, 7, 14 days</time_frame>
    <description>tmax calculated from serum transferrin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>predose and postdose 5 minutes, 2 hours and 1, 4, 7, 14 days</time_frame>
    <description>Cmax calculated from serum transferrin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ</measure>
    <time_frame>predose and postdose 5 minutes, 2 hours and 1, 4, 7, 14 days</time_frame>
    <description>AUCτ calculated from serum transferrin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>predose</time_frame>
    <description>Ctrough calculated from serum transferrin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>17 weeks</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>β-thalassemia Intermedia</condition>
  <arm_group>
    <arm_group_label>human apotransferrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive one intravenous loading dose of human apotransferrin on Day -1 followed by the maintenance dose every two weeks from Day 0 onwards for 14 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human apotransferrin</intervention_name>
    <description>Intravenous infusions</description>
    <arm_group_label>human apotransferrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-transfusion dependent β-thalassemia intermedia, defined as patients with
             microcytic anaemia in combination with an elevated HbA2 (&gt;2.5%) and a haemoglobin of
             &lt;6.2 mmol/L, or transfusion dependent β-thalassemia treated with a regular transfusion
             schedule.

          -  Age above≥ 17 years.

          -  Adequate renal and hepatic function tests

          -  WHO performance 0, 1 or 2.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Known with allergic reactions against human plasma or plasma products.

          -  Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes,
             infection, hypertension, pulmonary disease).

          -  Cardiac dysfunction as defined by: myocardial infarction within the last 6 months of
             study entry, unstable angina, or unstable cardiac arrhythmias.

          -  Pregnant or lactating females.

          -  Known with IgA deficiency with anti-IgA antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Biemond, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilona Kleine Budde, PhD</last_name>
    <phone>+31205123537</phone>
    <email>i.kleinebudde@sanquin.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roel Romij</last_name>
    <email>hemat.trial@amc.uva.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam-Zuidoost</city>
        <state>Noord-Holland</state>
        <zip>1100 DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart J Biemond, PhD, MD</last_name>
      <phone>+31 20 566 5785</phone>
      <email>b.j.biemond@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Bart J Biemond, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>June 19, 2019</last_update_submitted>
  <last_update_submitted_qc>June 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

